All In Biotech

Drug Trial Radar · NCT05848440

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Last checked: Nov 19, 2026Latest source record: Dec 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

May 2, 2023

Primary completion

Nov 13, 2023

Study completion Nov 13, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
May 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants.

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

  • AZD9550Drug

    Participants will be administered AZD9550 subcutaneously.

  • AZD9550Drug

    Participants will be administered AZD9550 intravenously.

  • PlaceboDrug

    Participants will be administered matching volumes of placebo subcutaneously or intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Throughout the study (up to 6 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Harrow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.